Picture loading failed.

Pre-Made Balstilimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Balstilimab emerged from a research programme comprising monoclonal antibody therapeutics [see ADIS Insight drug profile 800034205]. Company Agreements.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-044-1mg 1mg 3090
GMP-Bios-ab-044-10mg 10mg Inquiry
GMP-Bios-ab-044-100mg 100mg Inquiry
GMP-Bios-ab-044-xmg ≥100mg Inquiry
Shipping Cost: 760.00
Total:



Description

Products Name (INN Index) Pre-Made Balstilimab biosimilar, Whole mAb, Anti-PDCD1/PD-1 Antibody: Anti-CD279/PD1/SLEB2/hSLE1 therapeutic antibody
INN Name Balstilimab
TargetPDCD1/PD-1
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG4
VD LCKappa
Highest_Clin_Trial (Jan '20)Preregistration
Est. StatusActive
100% SI StructureNone
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2018
Year Recommended2019
CompaniesAgenus;Ludwig Institute for Cancer Research
Conditions Approvedna
Conditions ActiveCervial cancer;Solid tumours;Colorectal cancer;Haemangiosarcoma;Soft tissue sarcoma
Conditions Discontinuedna
Development Techna